Abstract

Envista Holdings will report fiscal second-quarter results on August 5, 2026 Post Market, and consensus expects continued top-line expansion alongside improving profitability metrics, with investor attention on mix shifts toward higher-value categories, operating leverage, and the cadence of margin recovery across key franchises.

Market Forecast

Based on prevailing estimates, Envista Holdings’ fiscal second-quarter revenue is projected at 716.05 million US dollars, up 11.85% year over year, with adjusted EPS expected at 0.34, up 43.12% year over year; EBIT is forecast at 87.68 million US dollars, up 16.97% year over year. Formal gross margin and net margin guidance for the quarter has not been issued, and external expectations are anchored to last quarter’s margin improvements and mix dynamics rather than company-specific quarterly margin targets. Across its core portfolio, the company’s revenue base remains balanced between higher-value Specialty Products & Technologies and the more recurring Equipment & Consumables stream, with continued execution in aligners, implants, imaging, and consumables expected to underpin mid-teens growth in value-led categories and a progressively more favorable margin mix. The most promising segment remains Specialty Products & Technologies, which delivered 457.80 million US dollars last quarter, up 14.40% year over year, paced by aligners and orthodontics momentum and resilient implant demand outside select geographies.

Last Quarter Review

For the fiscal first quarter ended April 3, 2026, Envista Holdings reported revenue of 705.50 million US dollars, a gross profit margin of 55.73%, GAAP net profit attributable to the parent company of 38.70 million US dollars with a net profit margin of 5.49%, and adjusted EPS of 0.36, up 50.00% year over year. Quarter-on-quarter, net profit grew by 17.63%, reflecting early operating leverage from revenue growth and an improving cost structure. Main business highlights included Specialty Products & Technologies revenue of 457.80 million US dollars and Equipment & Consumables revenue of 247.70 million US dollars, each up 14.40% year over year, supported by double-digit aligner growth and stable demand in imaging and consumables.

Current Quarter Outlook

Main business trajectory and levers to earnings quality

The near-term setup for Envista Holdings’ consolidated business is led by the carry-through of pricing discipline and mix, particularly from higher-value Specialty Products & Technologies and the recovery in Equipment & Consumables orders as clinical volumes normalize. The projected revenue of 716.05 million US dollars, if realized, implies continued mid-teens year-over-year expansion in value-accretive categories and incremental operating leverage against largely stable operating expenses. With adjusted EPS expected to rise 43.12% year over year to 0.34, the market is embedding a margin uplift from mix, procurement savings, and disciplined SG&A deployment, on top of the scale benefits of higher volumes. Quarterly margin direction will likely hinge on product and regional mix. Last quarter’s 55.73% gross margin provides a constructive baseline, and the consolidation of higher-margin orthodontic and implant workflows can help offset typical seasonal patterns in capital equipment. In parallel, the 5.49% net margin leaves room for incremental improvement as EBIT scales and financing costs remain contained, with consensus EBIT of 87.68 million US dollars indicating broader operating expansion. Execution in consumables and imaging is equally important to underpin quarter-to-quarter stability. Consumables typically provide recurring cash generation and better visibility, while imaging demand is tied to practice investments that can extend cycle times; clearer visibility on order intake, shipment timing, and conversion to revenue will shape whether the quarter tracks at or above the midpoint of consensus. Taken together, the balance of recurring and value-led categories sets a foundation for achieving the double-digit sales growth implied by forecasts while supporting EPS accretion.

Most promising segment: Specialty Products & Technologies

Specialty Products & Technologies remains the key growth engine, having delivered 457.80 million US dollars last quarter, up 14.40% year over year, and benefiting from consistent double-digit momentum in clear aligners and orthodontics. Aligners continue to scale on broader case-mix adoption and international uptake, while orthodontic systems complement clear aligner workflows, improving practice economics and patient conversion. Outside of select geographies, implants demonstrated steady demand with mid-single-digit growth commentary, suggesting stable procedure volumes and steady pricing in major markets. This quarter, the path to outperformance in Specialty Products & Technologies rests on continued case starts in aligners and improved throughput in orthodontic brackets and wires, coupled with stable implant activity ex-China. Any cadence in order seasonality is likely to be offset by continued funnel depth and salesforce execution, while ongoing product enhancements and training ecosystems support better utilization rates. From a margin standpoint, this segment’s richer mix supports the consolidated EBIT outlook; further productivity from manufacturing and logistics optimization can add modest incremental margin over the quarter. China remains a watchpoint given policy-driven volume-based procurement in implants, which produced short-term pressure even as demand ex-China remained constructive; consequently, investors will look for evidence that diversified geographic exposure is smoothing the aggregate growth profile. Should aligners sustain double-digit growth while implants stabilize, segment-level gross margin should remain healthy, reinforcing the EPS growth implied by consensus.

Stock-price drivers this quarter

Two operational variables stand out as primary stock drivers: mix-led margin progression and the sustainability of double-digit revenue growth. If Specialty Products & Technologies continues to expand faster than the consolidated portfolio, the earnings algorithm should benefit from a richer mix and better gross-to-operating margin conversion, supporting the 16.97% year-over-year EBIT growth embedded in forecasts. Evidence that Equipment & Consumables orders are tracking steadily can reduce volatility and enhance cash generation, reinforcing the quarterly EPS trajectory. Capital deployment is another focal area. The 300.00 million US dollars share repurchase authorization through December 31, 2029 provides flexibility to offset dilution and support EPS. Any disclosure around buyback activity during the quarter or intended pacing into the back half of the fiscal year could bolster per-share metrics and investor confidence. Management’s strengthening of the finance function, including the appointment of a new chief accounting officer effective early August, may further support execution reliability and financial reporting cadence, both of which can improve valuation confidence when paired with consistent operating delivery. Finally, watch for the interplay between price, mix, and cost: procurement and logistics efficiencies realized last quarter can extend into this quarter, buffering any localized cost inflation. If gross margin trends hold near or above last quarter’s baseline while opex remains disciplined, the company can deliver on the consensus EPS inflection. Conversely, any delay in imaging shipments or a less favorable regional mix would primarily affect short-cycle revenue conversion rather than the broader earnings trajectory, given the company’s diversified revenue mix.

Analyst Opinions

Bullish views lead the current debate, with multiple major firms expecting improving execution and a favorable mix to drive upside to revenue and EPS through the year. One large global bank reiterates a Buy rating and a 32.00 US dollars price target, citing the combination of double-digit aligner growth, resilient implants outside specific geographies, and the operating leverage evident in the last quarter’s revenue, EBIT, and adjusted EPS beats versus consensus. Another well-known healthcare brokerage maintains a Buy rating with a 30.00 US dollars price target, pointing to attractive valuation relative to expected full-year adjusted EPS of 1.35–1.45 and anticipating continued share gains in aligners and orthodontics as product and commercial investments translate into higher case starts. These bullish perspectives align with the quarter’s setup: revenue projected to rise 11.85% year over year to 716.05 million US dollars, adjusted EPS expected to grow 43.12% year over year to 0.34, and EBIT forecast to expand 16.97% year over year to 87.68 million US dollars. Analysts in the bullish camp emphasize the improving quality of growth, noting that a larger share of revenue is being contributed by higher-margin technologies, which should enhance gross-to-operating margin conversion. They also highlight cash-return flexibility afforded by the multi-year repurchase authorization, which can dampen share-count drift and support per-share earnings in periods of transient operating variability. Importantly, the bullish case does not depend on aggressive changes to the demand environment; rather, it assumes steady execution on product cadence, pricing discipline, and cost controls, with geographically diversified demand smoothing localized policy or channel noise. Should reported results confirm continued double-digit growth in Specialty Products & Technologies and a stable run rate in Equipment & Consumables, the majority view expects the company to meet or modestly exceed quarterly expectations and reaffirm the trajectory implied by full-year targets.